This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.


Dosing the Antipsychotic Medication Olanzapine

Charles B. Nemeroff, M.D., Ph.D.

Published: August 1, 1997

Article Abstract

Olanzapine is a new antipsychotic agent with serotonin/dopamine antagonism action. Efficacy intreating overall psychopathology in acute schizophrenia as measured by the BPRS0-6 total score wasdemonstrated at 10 mg/day versus placebo; at doses in a 5-20 mg/day range, olanzapine was comparableor superior to haloperidol. Superior efficacy for negative and depressive symptoms was shownin comparison to haloperidol. Olanzapine has a favorable acute and tardive extrapyramidal symptomprofile relative to haloperidol and caused substantially less elevation of serum prolactin. Dose-relatedweight gain and asymptomatic mild transaminase elevations occurred in olanzapine-treated patients.

Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Volume: 58

Quick Links: Psychotic Disorders , Schizophrenia and Schizoaffective Disorders

Sign-up to stay
up-to-date today!


Already registered? Sign In

Original Research

Young-Adult Social Outcomes of Attention-Deficit/Hyperactivity Disorder

ADHD that persisted into young-adulthood was associated with poorer outcomes in terms of education, employment, and emotional...